BPC-157 vs GHK-Cu

Side-by-side comparison of BPC-157, GHK-Cu — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute BPC-157 Body Protection Compound-157 Recovery GHK-Cu Glycyl-L-Histidyl-L-Lysine Copper Complex Recovery
Basics
Molecular type Gastric PentadecapeptideCopper-Binding Tripeptide
Amino acids 153
Molecular weight 1,419.5 Da340.4 Da
Half-life ~4 hrs (SC)Short (minutes to hours)
Route(s) Subcutaneous, Intramuscular, Oral (research only)Subcutaneous, Topical (skin), IV (research)
Mechanism & Research
Primary mechanism BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… GHK-Cu forms a stable complex with copper(II), which is essential for its biological activity. The copper complex activates collagenase and other metalloproteinases that remodel damaged extracellular matrix while simulta…
Research status Research Compound Research Compound
Evidence summary The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… GHK-Cu is one of the most thoroughly researched cosmetic and wound-healing peptides. Topical GHK-Cu is commercially used in skincare. Deeper systemic applications (anti-aging, neuroprotection, systemic collagen support) …
Protocol & Dosing
Typical dose 200–500 mcg per injection1–2 mg/day (SC); topical as needed
Frequency Once or twice dailyDaily
Duration 4–12 weeks8–12 weeks
Timing Near injury site when possibleAny time of day
Safety
Common side effects
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
  • Topical: mild skin irritation at application site
  • Injectable: injection site redness
  • Copper taste (topical — rare)
Contraindications
  • Active malignancy (theoretical growth stimulation concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
  • Wilson's disease (copper metabolism disorder)
  • Known copper sensitivity
  • Pregnancy (insufficient systemic safety data)
Anti-doping Prohibited (WADA S0) Not Prohibited
Deeper reading
Related peptides TB-500, GHK-Cu, KPV, Pentadeca Arginate BPC-157, Epithalon, LL-37
Full profile Read full BPC-157 profile → Read full GHK-Cu profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.